SBI Healthcare Opportunities Fund vs WhiteOak Capital Pharma and Healthcare Fund
Direct Plan, Growth option · Data as on 30-10-2026
SBI Healthcare Opportunities Fund is a Thematic fund and WhiteOak Capital Pharma and Healthcare Fund is a Sectoral fund. In the year to 30-10-2026, SBI Healthcare Opportunities Fund (Direct) returned 17.1% and WhiteOak Capital Pharma and Healthcare Fund (Direct) returned 19.5%. SBI Healthcare Opportunities Fund charges 1.01% a year and WhiteOak Capital Pharma and Healthcare Fund 1.07% (Direct plans). Their portfolios overlap 57.6%: they hold 27 of the same securities.
SBI Healthcare Opportunities Fund
Thematic
- 1 year return
- 17.1%
- Expense ratio
- 1.01%
- NAV
- ₹588.16
WhiteOak Capital Pharma and Healthcare Fund
Sectoral
- 1 year return
- 19.5%
- Expense ratio
- 1.07%
- NAV
- ₹17.44
Which is better, SBI Healthcare Opportunities or WhiteOak Capital Pharma and Healthcare? Key differences
It depends on what you want from the fund. These are the differences in numbers, from the data on this page.
- WhiteOak Capital Pharma and Healthcare returned more over 1 year: 19.5% against 17.1%.
- SBI Healthcare Opportunities costs less: 1.01% a year against 1.07% (Direct plans).
- SBI Healthcare Opportunities fell less in its worst fall since 07-02-2024: −13.5% against −15.4%.
- SBI Healthcare Opportunities is the larger fund: ₹5,870 Cr against ₹927 Cr.
- Their portfolios overlap 57.6%: 27 of the same holdings.
Past returns do not promise future returns. This page is information, not investment advice.
Key facts
From each fund's scheme summary document and AMFI
| Fact | SBI Healthcare Opportunities Fund | WhiteOak Capital Pharma and Healthcare Fund |
|---|---|---|
| Fund house | SBI Mutual Fund | WhiteOak Capital Mutual Fund |
| Category | Thematic | Sectoral |
| AUM | ₹5,870 Cr (30-09-2026) | ₹927 Cr (30-09-2026) |
| NAV | ₹588.16 (Direct) | ₹17.44 (Direct) |
| Expense ratio (Direct) | 1.01% | 1.07% |
| Expense ratio (Regular) | 1.99% | 2.75% |
| Riskometer | Not available | Very High |
| Benchmark | Not available | BSE Healthcare TRI |
| Launch date | Not available | 06-02-2024 |
| Minimum investment | Not available | ₹500 |
| Lock in | Not available | None |
| Fund managers | Not available | Ramesh Mantri, Piyush Baranwal, Dheeresh Pathak, Ashish Agrawal, Trupti Agrawal |
| Exit load | Not available | Nil |
SBI Healthcare Opportunities vs WhiteOak Capital Pharma and Healthcare: Returns Comparison
Returns as on 30-10-2026. Up to one year they are absolute returns. Longer periods are a rate per year.
| Fund | 1M | 3M | 6M | 1Y | 3Y | 5Y | 10Y |
|---|---|---|---|---|---|---|---|
| SBI Healthcare Opportunities Fund (Direct) | +0.31% | −0.59% | +16.00% | +17.12% | +24.60% | +19.22% | +14.72% |
| WhiteOak Capital Pharma and Healthcare Fund (Direct) | +0.92% | +1.33% | +17.99% | +19.53% | -- | -- | -- |
| Thematic average | −2.09% | −4.52% | +0.86% | −1.22% | +13.76% | +11.62% | +13.76% |
| Sectoral average | −1.70% | −4.49% | +2.30% | −0.58% | -- | -- | -- |
Category average: the average of the 235 Thematic funds and the 20 Sectoral funds, same plan type.
SBI Healthcare Opportunities vs WhiteOak Capital Pharma and Healthcare: Year-wise Returns
| Year | SBI Healthcare OpportunitiesSBI Healthcare Opportunities | WhiteOak Capital Pharma and HealthcareWhiteOak Capital Pharma and Healthcare | BSE Healthcare TRI |
|---|---|---|---|
| 2026to date | +21.31% | +22.83% | +15.08% |
| 2025 | −2.50% | +1.84% | −2.72% |
| 2024 | +43.75% | -- | +44.30% |
| 2023 | +39.72% | -- | +37.97% |
| 2022 | −5.01% | -- | −11.50% |
| 2021 | +21.48% | -- | +21.54% |
SBI Healthcare Opportunities vs WhiteOak Capital Pharma and Healthcare: Rolling Returns
Every holding period of both funds, against BSE Healthcare TRI, the benchmark of both
Rolling returns
Every 1-year holding period, 430 of them, one for each trading day from 07-02-2025 to 30-10-2026: the yearly return (CAGR) of each, plotted on the day it ended. One lucky or unlucky start day cannot flatter or hide a fund.
SBI Healthcare Opportunities Fund (Direct)
WhiteOak Capital Pharma and Healthcare Fund (Direct)
BSE Healthcare TRI
to
Mar 2025Jul 2024
to
Jul 2025Oct 2024
to
Oct 2025Feb 2025
to
Feb 2026May 2025
to
May 2026Sept 2025
to
Sept 2026
How the periods spread
| Fund | Below 0% | 0-5% | 5-10% | 10-15% | 15-20% | 20-25% | Above 25% | Mean | Median | Lowest | Highest | Beat benchmark |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| SBI Healthcare Opportunities | 7.9 | 16.0 | 15.1 | 17.2 | 16.7 | 24.9 | 2.1 | 12.4% | 12.7% | −3.3% | 27.7% | 83% |
| WhiteOak Capital Pharma and Healthcare | 0.0 | 6.6 | 14.9 | 16.3 | 18.6 | 19.3 | 24.3 | 18.0% | 18.4% | 0.6% | 35.5% | 100% |
| BSE Healthcare TRI | 9.5 | 19.3 | 17.0 | 24.9 | 20.5 | 8.8 | 0.0 | 10.2% | 10.9% | −3.7% | 24.8% | -- |
The table shows the % of periods in each return band; a darker cell holds more of them. Lumpsum: the yearly rate (CAGR) from a period's first NAV to its last. SIP: the XIRR of the monthly instalments. The benchmark is BSE Healthcare TRI, over the same periods. "Beat benchmark" counts the periods in which the fund did better. Every fund is measured over the days all of them have, from 07-02-2024. Past returns do not promise future returns.
SBI Healthcare Opportunities vs WhiteOak Capital Pharma and Healthcare: SIP and Lumpsum Returns
What the same monthly or one-time investment would be worth in each fund today, from their own NAV history
Growth of an investment
₹10,000 on the first trading day of every month, from 01-02-2024 to 30-10-2026: 33 instalments, ₹3,30,000 in all.
| Investment | Invested | Value now | Gain | Return a year |
|---|---|---|---|---|
| SBI Healthcare OpportunitiesSBI Healthcare Opportunities Fund (Direct) | ₹3,30,000 | ₹4,12,050 | ₹82,050 | 16.4% |
| WhiteOak Capital Pharma and HealthcareWhiteOak Capital Pharma and Healthcare Fund (Direct) | ₹3,30,000 | ₹4,37,625 | ₹1,07,625 | 21.2% |
SBI Healthcare OpportunitiesSBI Healthcare Opportunities Fund (Direct)
WhiteOak Capital Pharma and HealthcareWhiteOak Capital Pharma and Healthcare Fund (Direct)
Amount invested
From each plan's published NAV (Growth option), over the same days. Return a year: XIRR for a SIP, CAGR for a lumpsum, shown for a year or more. It does not include exit load, stamp duty or tax. Past returns do not promise future returns.
SBI Healthcare Opportunities vs WhiteOak Capital Pharma and Healthcare: Risk and Drawdowns
How much each fund swings, and the worst fall over the same days
Risk and return
| Measure | SBI Healthcare Opportunities Fund (Direct) | WhiteOak Capital Pharma and Healthcare Fund (Direct) |
|---|---|---|
| Return (CAGR) | +17.12% | +19.53% |
| Standard deviation | 13.36% | 13.75% |
| Sharpe ratio | 0.89 | 1.04 |
| Sortino ratio | 1.33 | 1.57 |
| Maximum drawdown | −10.3% (23-10-2026) | −9.8% (23-10-2026) |
| Beta | 0.93 | 0.97 |
| Alpha | +5.25% | +7.36% |
From daily NAVs, 30-10-2025 to 30-10-2026. Standard deviation: how much the daily value swings, scaled to a year. Sharpe: return above the risk-free rate (NSE's overnight rate index) per unit of swing. Sortino: the same, counting only the falls. Beta and alpha compare each fund with its own benchmark's TRI.
| Measure | SBI Healthcare Opportunities Fund (Direct) | WhiteOak Capital Pharma and Healthcare Fund (Direct) |
|---|---|---|
| Return (CAGR) | +17.93% | +22.30% |
| Standard deviation | 15.96% | 14.35% |
| Sharpe ratio | 0.74 | 1.14 |
| Sortino ratio | 1.05 | 1.62 |
| Maximum drawdown | −30.5% (23-03-2020) | −15.4% (28-02-2025) |
| Beta | 0.91 | 0.97 |
| Alpha | +3.97% | +7.59% |
From daily NAVs, 02-01-2013 to 30-10-2026. Standard deviation: how much the daily value swings, scaled to a year. Sharpe: return above the risk-free rate (NSE's overnight rate index) per unit of swing. Sortino: the same, counting only the falls. Beta and alpha compare each fund with its own benchmark's TRI.
Drawdowns
How far below its previous high each one was on every day: the falls an investor had to sit through. 0% means it was at a new high.
SBI Healthcare Opportunities Fund (Direct)
WhiteOak Capital Pharma and Healthcare Fund (Direct)
BSE Healthcare TRI
| Fund | Worst fall | High before it | Bottom | Back at the high | Time to climb back | Below its high today |
|---|---|---|---|---|---|---|
| SBI Healthcare Opportunities Fund (Direct) | −13.5% | 07-01-2025 | 28-02-2025 | 17-07-2025 | 5 months | −3.8% |
| WhiteOak Capital Pharma and Healthcare Fund (Direct) | −15.4% | 02-01-2025 | 28-02-2025 | 14-07-2025 | 4 months | −3.0% |
| BSE Healthcare TRI | −16.2% | 02-01-2025 | 28-02-2025 | 29-07-2025 | 5 months | −3.8% |
From daily values since 07-02-2024, the first day every fund has.
Rolling standard deviation
Whether the swings have grown or calmed over time: the standard deviation of daily changes over every 1-year window, scaled to a year, plotted on the window's last day. Higher means a bumpier ride.
SBI Healthcare Opportunities Fund (Direct)
WhiteOak Capital Pharma and Healthcare Fund (Direct)
BSE Healthcare TRI
Against BSE Healthcare TRI
| Fund | Up capture | Down capture | Tracking error |
|---|---|---|---|
| SBI Healthcare Opportunities Fund (Direct) | 97% | 83% | 3.71% |
| WhiteOak Capital Pharma and Healthcare Fund (Direct) | 116% | 90% | 3.43% |
From month-end values since 07-02-2024. Up capture: a fund's average month when the benchmark rose, as % of the benchmark's; above 100% it gained more. Down capture: the same for months the benchmark fell; below 100% it fell less. Tracking error: how far the monthly returns strayed from the benchmark's, a year; an index fund aims near 0.
SBI Healthcare Opportunities vs WhiteOak Capital Pharma and Healthcare: Portfolio Overlap
From each fund's latest monthly portfolio: SBI Healthcare Opportunities Fund, September 2026; WhiteOak Capital Pharma and Healthcare Fund, September 2026
Holdings in common
- Overlap
- 57.6%
- Held by both
- 27
- Only in SBI Healthcare Opportunities
- 9
- Only in WhiteOak Capital Pharma and Healthcare
- 32
| Security | % of SBI Healthcare Opportunities | % of WhiteOak Capital Pharma and Healthcare |
|---|---|---|
| Divi's Laboratories Ltd. | 7.91% | 8.36% |
| Sun Pharmaceutical Industries Ltd. | 11.14% | 7.11% |
| Torrent Pharmaceuticals Ltd. | 4.42% | 6.26% |
| Laurus Labs Ltd. | 4.05% | 3.91% |
| Apollo Hospitals Enterprise Ltd. | 4.45% | 3.75% |
| Cipla Ltd. | 4.40% | 3.68% |
| Sai Life Sciences Ltd. | 2.60% | 3.28% |
| Corona Remedies Ltd. | 2.43% | 2.34% |
| Aurobindo Pharma Ltd. | 3.42% | 2.09% |
| Max Healthcare Institute Ltd. | 3.80% | 1.84% |
| Ajanta Pharma Ltd. | 1.79% | 2.01% |
| Global Health Ltd. | 1.74% | 1.82% |
| Krishna Institute of Medical Sciences Ltd. | 1.69% | 1.85% |
| Dr. Lal Path labs Ltd. | 1.62% | 2.35% |
| Anthem Biosciences Ltd. | 2.75% | 1.57% |
| Acutaas Chemicals Ltd. | 5.03% | 1.45% |
| Fortis Healthcare Ltd. | 2.36% | 1.36% |
| Mankind Pharma Ltd. | 1.71% | 1.20% |
| Aether Industries Ltd. | 2.17% | 1.05% |
| Gland Pharma Ltd. | 2.96% | 0.93% |
| Jupiter Life Line Hospitals Ltd. | 2.16% | 0.73% |
| Rainbow Children's Medicare Ltd. | 0.67% | 1.15% |
| Innova Captab Ltd. | 1.65% | 0.63% |
| Nephrocare Health Service Pvt. Ltd. | 1.12% | 0.57% |
| Sudeep Pharma Ltd. | 2.79% | 0.46% |
| Biocon Ltd. | 2.37% | 0.42% |
| Novartis India Ltd. | 0.04% | 0.24% |
Overlap: for each holding both funds own, the smaller of its two weights, added up. 57.6% means 57.6% of each fund's money sits in positions the other also holds. Matched by ISIN. Cash and hedged positions are left out.
Largest holdings only in SBI Healthcare Opportunities Fund
| Security | % of fund |
|---|---|
| Aster DM Quality Care Ltd. | 3.21% |
| Concord Biotech Ltd. | 2.25% |
| Polymedicure Ltd. | 1.82% |
| Healthcare Global Enterprises Ltd. | 1.70% |
| Cohance Lifesciences Ltd. | 1.66% |
Largest holdings only in WhiteOak Capital Pharma and Healthcare Fund
| Security | % of fund |
|---|---|
| IPCA Laboratories Limited | 2.88% |
| Zydus Lifesciences Limited | 2.81% |
| Neuland Laboratories Limited | 2.60% |
| Thyrocare Technologies Limited | 2.27% |
| Shaily Engineering Plastics Limited | 1.84% |
Asset and sector split
Share of each fund, from its latest monthly portfolio
Asset allocation
| Asset | SBI Healthcare Opportunities | WhiteOak Capital Pharma and Healthcare |
|---|---|---|
| Equity | 95.5% | 90.7% |
| Debt | 0.1% | 3.1% |
| Cash and others | 4.4% | 6.1% |
Market cap of stocks
| Market cap | SBI Healthcare Opportunities | WhiteOak Capital Pharma and Healthcare |
|---|---|---|
| Large Cap | 32.3% | 29.2% |
| Mid Cap | 25.7% | 21.7% |
| Small Cap | 35.4% | 37.5% |
| Not on AMFI's list | 2.2% | 2.4% |
Share of the whole fund. Groups follow AMFI's latest list: Large Cap is the 100 largest companies, Mid Cap the next 150, Small Cap the rest.
Largest sectors
| Sector | SBI Healthcare Opportunities | WhiteOak Capital Pharma and Healthcare |
|---|---|---|
| Pharmaceuticals & Biotechnology | 63.1% | 61.2% |
| Healthcare Services | 25.6% | 23.0% |
| Chemicals & Petrochemicals | 5.0% | 3.3% |
| Consumer Durables | 0.0% | 1.8% |
| Healthcare Equipment & Supplies | 1.8% | 1.4% |
The six largest sectors of each fund's stocks, % of the fund.
SBI Healthcare Opportunities vs WhiteOak Capital Pharma and Healthcare: Expense Ratio
What each plan charges a year, from AMFI's expense ratio file
| Charge | SBI Healthcare Opportunities Fund | WhiteOak Capital Pharma and Healthcare Fund |
|---|---|---|
| Total expense ratio (Direct) | 1.01% | 1.07% |
| Base expense ratio (Direct) | 0.74% | 0.54% |
| Total expense ratio (Regular) | 1.99% | 2.75% |
| Base expense ratio (Regular) | 1.58% | 1.96% |
The expense ratio comes out of the fund's assets every day, so every return on this page is already after it. Base expense ratio: the fund house's own fee. The total adds brokerage, transaction costs, and levies with GST.
More comparisons
Each fund against the others of its category
Compare SBI Healthcare Opportunities with
Compare WhiteOak Capital Pharma and Healthcare with
- WhiteOak Capital Pharma and Healthcare vs DSP Healthcare
- WhiteOak Capital Pharma and Healthcare vs Nippon India Pharma
- WhiteOak Capital Pharma and Healthcare vs Bandhan Transportation and Logistics
- WhiteOak Capital Pharma and Healthcare vs Nippon India Power & Infra
- WhiteOak Capital Pharma and Healthcare vs Invesco India Financial Services
SBI Healthcare Opportunities Fund vs WhiteOak Capital Pharma and Healthcare Fund: Frequently Asked Questions
What is the difference between SBI Healthcare Opportunities Fund and WhiteOak Capital Pharma and Healthcare Fund?
SBI Healthcare Opportunities Fund is a Thematic fund, WhiteOak Capital Pharma and Healthcare Fund is a Sectoral fund, run by SBI Mutual Fund and WhiteOak Capital Mutual Fund. Their portfolios overlap 57.6%. SBI Healthcare Opportunities Fund charges 1.01% a year and WhiteOak Capital Pharma and Healthcare Fund 1.07%.
Which has given higher returns, SBI Healthcare Opportunities Fund or WhiteOak Capital Pharma and Healthcare Fund?
Over 1 year: SBI Healthcare Opportunities Fund +17.12%, WhiteOak Capital Pharma and Healthcare Fund +19.53%. As on 30-10-2026. Past returns do not promise future returns.
Which has the lower expense ratio, SBI Healthcare Opportunities Fund or WhiteOak Capital Pharma and Healthcare Fund?
SBI Healthcare Opportunities Fund charges less: 1.01% a year against 1.07%. These are the Direct plans' total expense ratios reported to AMFI.
How much do SBI Healthcare Opportunities Fund and WhiteOak Capital Pharma and Healthcare Fund overlap?
57.6%. They hold 27 of the same securities, the largest shared ones being DIVISLAB, SUNPHARMA, TORNTPHARM. From each fund's latest monthly portfolio.
Can I invest in both SBI Healthcare Opportunities Fund and WhiteOak Capital Pharma and Healthcare Fund?
Yes. 57.6% of each fund's money sits in the same holdings, so a large part of the two investments would move together.
Sources: NAV and expense ratio from AMFI. Holdings from each fund house's monthly portfolio statement. Fund facts from each scheme summary document.
This page is information, not investment advice. Mutual fund investments are subject to market risks; read all scheme related documents carefully. Past returns do not promise future returns. Figures come from AMFI, NSE, BSE and each fund house's own documents.